- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025
- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025

IMCAS Academy

Introduction
Evaluation
Register
Program
Speakers
Gala
Plan your trip
Sponsor list
Accreditation

GO BACK

IMCAS Asia 2025
Program

Adapt the schedule of the livestreamed class/congress to your time zone

Time zone reference: (UTC+07:00) Asia, Bangkok

Time zone

Time zone:Change time zone

If you are logged in, change your default time zone in your account

Vascular laser updates

Room: Room 6 - Level 3
Date: Saturday 7 June 2025 at 16:30 to 18:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Chairs

Dr Jane Ratna Maitri Dewi OEIRIA

Dermatologist

Indonesia

Dr Poonkiat SUCHONWANIT

Dermatologist

Thailand

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
16:30	Dr Anil GANJOO	Yellow Diode laser for Vascular lesions	View	146959
16:43	Dr Johannes Flores DAYRIT	Rosacea in skin of color: Updates and challenges	View	146958
16:56	Dr Hugues CARTIER	Bruising, which laser is the best for		146961
17:09	Dr Wonkyu HONG	Post-Acne Erythema Reimagined: Integrating Spicule-Based Peptide Delivery with Vascular Laser Therapy	View	149471
17:22	Prof Chee Leok GOH	Choosing vascular lasers for vascular lesions – an update	View	146960
17:35		Discussion and Q&A		146962

Go to previous session

Go to next room (Open Stage - Level 2)

Recommended sessions

Vascular lesions

Lasers

Upper face & forehead (non-surgical)

Rosacea

Skin phototype (type I, etc)

Dr Anil GANJOO

Dermatologist

India

Other author(s) :

Yellow Diode laser for Vascular lesions

Objectives: The gold standard treatment for the vascular lesions has been the Pulse Dye Laser. However, this laser is very expensive and the maintenance is very difficult. The expensive dye is a consumable and makes the treatment cost very high.
The diode lasers have revolutionised the l;aser worrld by their abilty to produce all kinds of wave lengths.
We have been working on a diode yellow laser for vascular lesions and have got quite gratifying results

Introduction: Following lasers can be used for treating vascular lesions
532 nm KTP laser.

585 nm pulsed dye laser.

755 nm Alex laser.

1064 nm Nd : YAG laser
However, now the diode lasers that can produce any wavelength can be used for multiple indications including for thje vascular lesions

Here we use a very vascular specific wavelength of 577nm

Materials / method: A semiconductor laser converts electric energy into light energy

This happens because of the partial conduction properties of the semiconductor material

By putting specific amounts of impurities into the semiconductor material(doping) the number of negative and positive electrons can be changed

This can help us produce different wavelengths from the same semiconductor

A YELLOW laser at 577 nm, is considered the best choice for vascular treatments:
It is the OPTIMUM WAVELENGTH OF 577nm FOR SUPERIOR RESULTS
577nm matches the absorption peak of hemoglobin
577nm has 39% more blood absorption

Results: Therefore
There is more blood absorption making it more effective
Less Fluence is needed so less side effects

Less melanin absorption also ensures
less side effects particularly in darker skin

Conclusion: The yellow diode laser is a huge advancement for the treatment of the vascular lesions
A solid-state laser, low costs, easy maintenance
The older gold standard pulsed due lasers had the disadvantages of
Large devices
Very expensive machines
High recuring cost of the dye

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Johannes Flores DAYRIT

Dermatologist

Philippines

Other author(s) :

Rosacea in skin of color: Updates and challenges

Objectives: To identify and properly classify the clinical phenotypes of rosacea among patients with Fitzpatrick skin phototypes III-V . To identify primary and secondary features, aggravating factors and extracutaneous manifestations. To discuss updates and challenges on the management of rosacea in skin of color.

Introduction: There has always been a erroneous perception that rosacea is rare in skin of color but in recent years, more cases of rosacea have been identified in African, Latino, and Asian population. Because it is difficult to detect erythema in darker skin phototypes, it has been underdiagnosed, misdiagnosed, undertreated and sub-optimally treated.

Materials / method: This was an observational cross-sectional study conducted among patients in a private clinic evaluating clinical features using the rosacea clinical scorecard and the 2017 standard classification by the National Rosacea Society expert committee. The duration of the disease, the subtype, aggravating factors, ocular symptoms, comorbidities , and subtype severity were likewise identified. Appropriate medical treatment and other adjunctive modalities such lasers to address erythema, inflammatory papules and pustules and erythema. Potential complications will be highlighted.

Results: A total of 413 (345 F; 68 M) patients were enrolled . Forty eight percent of patients presented with persistent centrofacial erythema, validated by 3D imaging. Phymas were present in 16% of cases. Transient facial redness with papules, pustules, and nodules were present in 52% of cases. Ocular symptoms constituted 4% of cases. Heat, sun exposure, emotional stress, and intake of alcoholic beverages were identified as the most common aggravating factors. Flushing is generally more pronounced in the papulopustular subtype, during menstruation and pregnancy. Majority of treatments were successful

Conclusion: The clinical characteristics of rosacea among Filipinos were identified. Although previously considered as rare among Asians, the study shows that it is common among Filipinos with brown skin. This seems to be related to Spanish and Chinese racial influence, vascular and sebaceous gland hyperreactivity and natural instrinsic responses to heat and sunlight. The presence of rosacea should always be considered when contemplating on performing aesthetic procedures since most patients are inflammatory and may experience potential complications such as burns and hyperpigmentation

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Hugues CARTIER

Dermatologist

France

Other author(s) :

Bruising, which laser is the best for

Dr Wonkyu HONG

Dermatologist

South Korea

Other author(s) :

Post-Acne Erythema Reimagined: Integrating Spicule-Based Peptide Delivery with Vascular Laser Therapy

Objectives: Understand the synergistic effects of combining vascular laser therapy with spicule-mediated peptide delivery in the treatment of post-acne erythema.

Learn how micro-invasive peptide systems can enhance outcomes in inflammation-prone and sensitive skin types.

Evaluate clinical tolerance, downtime, and efficacy compared to conventional monotherapies.

Introduction: Post-acne erythema remains a common aesthetic concern, often persisting long after acne resolution, especially in sensitive or vascular-reactive skin. Vascular lasers such as pulsed-dye and long-pulsed Nd:YAG remain mainstays for targeting redness; however, their results can be inconsistent, and recurrence is common. Recently, interest has grown in combining energy-based treatments with biologically active systems that repair the skin barrier, modulate inflammation, and enhance dermal recovery.

Materials / method: A micro-invasive peptide delivery system utilizing marine sponge-derived spicules was employed. The spicules were chemically bonded with anti-inflammatory peptides activated via glutathione. These were applied topically immediately following treatment with vascular lasers (e.g., Vbeam).

Assessment metrics included:
Reduction in erythema
Patient-reported tolerance and downtime
Improvement in skin texture and inflammatory lesion count

Results: Patients who received the combination protocol exhibited:
Faster reduction in post-acne erythema compared to laser-only treatment
Improved tolerance with less reported dryness and pruritus due to barrier-supportive post-care
Visible textural improvement and pore minimization, attributed to sustained peptide release over 72 hours
Downtime was limited to mild erythema lasting <24 hours in most patients

Conclusion: Combining vascular laser therapy with spicule-based peptide systems provides a powerful dual mechanism for resolving post-acne inflammation and enhancing skin quality. This protocol leverages the precision of laser targeting with the biological repair offered by extended peptide diffusion—offering a safe, non-injectable alternative for patients prioritizing minimal downtime and visible improvement.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): SR Biotek

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): SR Biotek

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): SR Biotek

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SR Biotek

Prof Chee Leok GOH

Dermatologist

Singapore

Other author(s) :

Choosing vascular lasers for vascular lesions – an update

Objectives: improves knowldge on treatment of vascular disorders.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Discussion and Q&A

CONGRESS

N O W

IN BANGKOK

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Asia
IMCAS China
IMCAS World Congress
IMCAS Americas

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS Asia 2025 Program

Vascular laser updates

Chairs

Lectures of the session

Recommended sessions

IMCAS Asia 2025
Program